|Bid||20.99 x 0|
|Ask||21.00 x 0|
|Day's Range||20.40 - 21.45|
|52 Week Range||11.20 - 23.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.71|
LAVAL, Quebec , Nov. 21, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has closed its ...
LAVAL, Quebec , Nov. 21, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Paul S. Herendeen , executive vice president, ...
Valeant Pharmaceuticals (NYSE:VRX) aced its third quarter, but while many on Wall Street were thrilled to see the biotech giant take a stride forward after quite a volatile year, better risk/reward is not enough to sway Deutsche Bank analyst Gregg Gilbert from the sidelines. What has left Gilbert cautiously optimistic on the company's recovery, but dialing down his price target?
US companies with rocky histories in the leveraged loan market, including vitamin and supplement retailer GNC Holdings Inc, weight loss company Weight Watchers International and specialty drug maker Valeant Pharmaceuticals International, are turning to the high-yield bond market to help refinance large existing loans, sources said. The bond market generally offers eight- to 10-year maturities while the loan market offers six- or seven-year tenors. GNC is attempting to refinance for the second time this year after a previous loan market attempt failed in May. The company cancelled its deal after investors asked for higher pricing to compensate for the risk associated with lending to a ‘brick and mortar’ retailer.
Yup! Things seem to be looking up for Valeant Pharmaceuticals International (VRX). The drug maker reported third quarter per-share profit that blew past expectations, albeit lowered expectations. Moody’s ...
LOS ANGELES , Nov. 16, 2017 /PRNewswire/ -- TroyGould advised Haitong International Zhonghua Finance Acquisition Fund I, L.P. (the "Fund") in its $190 million cash acquisition of the Obagi Medical ...
LAVAL, Quebec, Nov. 15, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, today announced that its unique ONE by ONE Recycling Program has recycled a combined total of more than one million used contact lenses, blister packs and top foils in less than one year since its launch. Made possible through a collaboration with TerraCycle®, a world leader in the collection and repurposing of hard-to-recycle post-consumer waste, the ONE by ONE Recycling Program has diverted more than 7,000 pounds of waste from landfills. "We are globally committed to environmental sustainability while also delivering innovations that meet the needs of our physicians and their patients," said Joseph C. Papa, chairman and CEO, Valeant.
Valeant Pharmaceuticals International Inc. has been directed by the Securities and Exchange Commission to clean up its use of nonstandard numbers, but the company is now sending one number to reporters ...
LAVAL, Quebec, Nov. 14, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (VRX) (VRX) ("Valeant" or the "Company") announced today that it has priced its previously announced offering of $750,000,000 aggregate principal amount of its 5.500% senior secured notes due 2025 (the "Notes"). The Notes will be additional notes and form part of the same series as Valeant's existing 5.500% senior secured notes due 2025. Valeant intends to use the net proceeds from the offering of the Notes, along with cash on hand, to repay (on a pro rata basis) a portion of its outstanding Series F Tranche B Term Loan Facilities due 2022 and to pay related fees and expenses.
Valeant Pharmaceuticals (NYSE:VRX) has attracted a great deal of positive Street buzz after last Tuesday's posted third quarter beat. BMO analyst Gary Nachman is out with a cautiously optimistic bumping up his price target a dollar. Yet, it is not all clear, cloudless skies for the biotech giant quite yet. Why is Nachman cautious?
"Since 2013, the Ortho Dermatologics Aspire Higher Scholarship program has recognized students that have not allowed skin conditions like psoriasis, eczema and severe acne to stand in the way of their academic achievements. Three scholarships were awarded in each of three categories: Undergraduate Scholar Awards for students pursuing an undergraduate degree, Graduate Scholar Awards for students pursuing a graduate degree and Today's Woman Scholar Awards for students who are mothers pursuing higher education.
The notes are due in 2025. Proceeds from the offering will help pay down some of Valeant's more than $26 billion debt load.
Last week, Valeant Pharmaceuticals International (VRX) rallied after the drug maker unveiled an estimate-beating earnings report that reassure investor that it was making progresses rebuilding itself after following a series of investigations into the drug maker’s accounting and pricing practices. Also helping fuel the upswing, Valeant reduced its total debt by $6 billion since the first quarter of 2016. Today, the shares are pulling back following Valeant’s launch of a $750 million debt offering.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Valeant Pharmaceuticals International, Inc. Here are 5 ETFs with the largest exposure to VRX-CA. Comparing the performance and risk of Valeant Pharmaceuticals International, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)
Valeant Pharmaceuticals (NYSE:VRX) has gotten some of the Street excited after a much-needed third quarter beat to re-ignite confidence after a string of litigations and investigations came to haunt the giant. Yet, what makes Wells Fargo analyst David Maris dismiss market enthusiasm as overblown?
Valeant Pharmaceuticals International Inc. said Monday it was launching a private offering of $750 million worth of notes due 2025, paying 5.500%. The drug maker plans to use the proceeds from the debt ...
LAVAL, QUEBEC, Nov. 13, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (VRX) (VRX) ("Valeant" or the "Company") announced today that it has launched an offering of $750,000,000 aggregate principal amount of 5.500% senior secured notes due 2025 (the "Notes"). The Notes will be additional notes and form part of the same series as Valeant's existing 5.500% Senior Secured Notes due 2025. Valeant intends to use the net proceeds from the offering of the Notes, along with cash on hand, to repay (on a pro rata basis) a portion of its outstanding Series F Tranche B Term Loan Facilities due 2022, and to pay related fees and expenses.